Physician profile
Candice Chambers
NPI 1093300998
$707.23
in general payments reported to CMS, 2019-2025
10 companies · $389 in 2025
The $389 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $21.74 · 2023: $93.19 · 2024: $203 · 2025: $389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $685.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $685.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $427.64 | 2024-2025 | |
| Lilly USA, LLC | $76.72 | 2023-2025 | Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $44.61 | 2023-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.57 | 2022-2023 | Relistor |
| Viiv Healthcare Company | $28.62 | 2025 | Apretude |
| Ardelyx, INC. | $27.13 | 2025 | Ibsrela |
| Novo Nordisk INC | $22.66 | 2025 | Ozempic, Rybelsus |
| Pfizer INC. | $17.49 | 2024 | |
| Abbvie INC. | $14.52 | 2023 | |
| Glaxosmithkline, LLC. | $13.27 | 2023 | Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Candice Chambers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.